Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
On August 11, 2022, Celcuity announced key developments including the FDA granting Breakthrough Therapy designation for its drug gedatolisib in treating HR+/HER2- advanced breast cancer. The company entered into a $100 million private placement agreement and expanded its debt facility from $25 million to $75 million to finance operations through 2025. The Phase 3 VIKTORIA-1 clinical trial is on track to begin dosing patients soon. Despite a net loss of $10 million in Q2 2022, operating expenses were reduced significantly, indicating a focus on maintaining financial health.
- FDA Breakthrough Therapy designation for gedatolisib.
- Successful $100 million private placement to fund operations through 2025.
- Reduced total operating expenses from $13.6 million in Q2 2021 to $9.6 million in Q2 2022.
- Ongoing Phase 3 VIKTORIA-1 trial expected to initiate soon.
- Net loss of $10 million in Q2 2022, though improved from $14 million in Q2 2021.
- Increased net cash used in operating activities from $7.6 million in Q2 2021 to $11.3 million in Q2 2022.
- G&A expenses rose to $1.2 million in Q2 2022 from $0.6 million in Q2 2021.
- Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancer
- Entered into agreements for the private placement sale of
$100 million of equity and to increase available debt facility from$25 million to$75 million - The Phase 3 VICTORIA-1 clinical trial remains on track to dose the first patient in the next few months
- Management to host webcast and conference call today, August 11, 2022, at 4:30 p.m. ET
MINNEAPOLIS, MN / ACCESSWIRE / August 11, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced financial results for the second quarter ended June 30, 2022 and other recent business developments.
"We made progress on a variety of fronts in the second quarter of 2022. The Breakthrough Therapy Designation recently granted to gedatolisib by the FDA will facilitate close collaboration with the agency as we seek to advance this therapy to the clinic as quickly as possible. Our early phase study evaluating gedatolisib in combination with palbociclib and fulvestrant in patients with advanced breast cancer whose disease progressed on a CDK4/6 inhibitor, reported promising efficacy, with high response rates, and tolerability, with low discontinuation rates due to adverse events. We are now excited to take the next step in the development of this potential first-in-class PI3K/mTOR inhibitor. Our Phase 3 clinical trial, VIKTORIA-1, remains on track to dose the first patient in the next few months," said Brian Sullivan, CEO and Co-Founder of Celcuity.
"We also made great progress strengthening our balance sheet over the past few months to support the clinical development of gedatolisib. The
Second Quarter 2022 Business Highlights and Other Recent Developments
- In May, Celcuity entered into a definitive securities purchase agreement with certain institutional and other accredited investors in a private placement for the purchase of common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred stock that is expected to result in aggregate proceeds to the Company of
$100 million before deducting placement agent fees and other offering expenses. Investors included Venrock Healthcare Capital Partners, Commodore Capital, New Enterprise Associates (NEA), RA Capital Management, Soleus Capital, and Brian Sullivan, the Company's Chief Executive Officer. The closing of the private placement is expected to occur shortly after the first patient in VIKTORIA-1 receives their first dose of treatment at a clinical site located in the United States, provided that such date must occur on or before December 31, 2022. - In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Celcuity's lead drug product candidate gedatolisib, an investigational pan-PI3K/mTOR inhibitor, for the treatment of HR+/HER2- locally advanced, inoperable or metastatic breast cancer that has progressed after treatment with a CDK4/6 inhibitor in combination with a nonsteroidal aromatase inhibitor. This designation allows for more intensive guidance from the FDA and a potentially accelerated review time if relevant criteria are met. Gedatolisib previously received Fast Track designation from the FDA in January 2022.
- This week, Celcuity amended its existing debt financing agreement with an affiliate of Innovatus Capital Partners, LLC ("Innovatus") to provide Celcuity with up to
$75 million in term loans, a$50 million increase from the original debt financing agreement. Celcuity received$15 million at the closing of the original agreement in April 2021. Celcuity will be able to draw an additional$20 million tranche following the closing of the$100 million private placement. Celcuity will be able to draw on two additional tranches of$10 million each and one additional tranche of$20 million upon achievement of certain clinical trial and financing milestones. Celcuity is entitled to make interest only payments for the 48-month period from the original agreement date or for the 60-month period from the original agreement date if certain conditions are met. The loans will mature on the sixth anniversary of the initial funding date. Innovatus has the right to convert outstanding principal into shares of Celcuity common stock until the third anniversary of the loan amendment date, with such amount limited to an aggregate of up to$6.6 million assuming all tranches are funded. The loan is secured by all of Celcuity's assets. Armentum Partners LLC acted as sole advisor to Celcuity for this transaction. - The VIKTORIA-1 Phase 3 clinical trial remains on track to dose the first patient in the next few months. The operational activities required to initiate the clinical trial at a study site are completed. The clinical trial protocol was updated to include an additional study arm (Arm F) to evaluate gedatolisib plus fulvestrant in 50 patients who have PIK3CA mutations. This update was made in response to a recommendation from the European Medicines Agency (EMA) that the study arms for PIK3CA mutated patients mirror the same study arms for PIK3CA non-mutated patients. No changes were made to the primary endpoints. VIKTORIA-1 will evaluate the safety and efficacy of gedatolisib in combination with fulvestrant with or without palbociclib in adults with HR+/HER2- advanced breast cancer whose disease progressed while receiving prior CDK4/6 therapy.
- Enrollment remains ongoing in the FACT-1 and FACT-2 trials for CELsignia selected patients who have early-stage HR+/HER2- breast cancer with interim results expected in mid-2023.
Second Quarter 2022 Financial Results
Unless otherwise stated, all comparisons are for the second quarter ended June 30, 2022, compared to the second quarter ended June 30, 2021.
The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes on Form 10-Q for the second quarter ended June 30, 2022. Total operating expenses were
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Net loss for the second quarter of 2022 was
Net cash used in operating activities for the second quarter of 2022 was
Webcast and Conference Call Information
The Celcuity management team will host a webcast/conference call at 4:30 p.m. ET today to discuss the second quarter 2022 financial results and provide a corporate update. To participate in the teleconference, domestic callers should dial 1-877-407-0784 and international callers should dial 1-201-689-8560 and reference conference ID: 13731012. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1557419&tp_key=2043138d9a. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer and expects to dose the first patient in the next few months. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.
About Innovatus Capital Partners, LLC
Innovatus Capital Partners, LLC, is an independent adviser and asset management firm with approximately
Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements" including, but not limited to, the timing of initiating and enrolling patients in clinical trials and receiving results from such trials, including without limitation, Celcuity's planned Phase 3 clinical trial (VIKTORIA-1), the costs and expected results from any ongoing or planned clinical trials, expectations with respect to planned clinical collaborations, the expected timing of funding for our private placement and additional tranches under our debt financing agreement, and expectations with respect to available cash to fund operations. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends" or "continue," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, the unknown impact of the COVID-19 pandemic on Celcuity's business and those other risks set forth in the Risk Factors section in Celcuity's Quarterly Report for the period ended March 31, 2022 filed with the Securities and Exchange Commission on May 16, 2022. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123
ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886
Celcuity Inc.
Condensed Balance Sheets
| June 30, 2022 | December 31, 2021 | |||||||
| (unaudited) | ||||||||
Assets | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 66,910,824 | $ | 84,286,381 | ||||
Deposits | 22,009 | 22,009 | ||||||
Deferred transaction costs | 332,824 | 22,144 | ||||||
Payroll tax receivable | 95,300 | 298,764 | ||||||
Prepaid assets | 4,601,874 | 722,677 | ||||||
Total current assets | 71,962,831 | 85,351,975 | ||||||
Property and equipment, net | 238,629 | 312,444 | ||||||
Operating lease right-of-use assets | 148,727 | 241,901 | ||||||
Total Assets | $ | 72,350,187 | $ | 85,906,320 | ||||
Liabilities and Stockholders' Equity: | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 2,304,543 | $ | 1,507,099 | ||||
Finance lease liabilities | 5,379 | 5,850 | ||||||
Operating lease liabilities | 156,769 | 189,858 | ||||||
Accrued expenses | 1,683,305 | 802,893 | ||||||
Total current liabilities | 4,149,996 | 2,505,700 | ||||||
Finance lease liabilities | - | 2,449 | ||||||
Operating lease liabilities | - | 61,771 | ||||||
Note payable, non-current | 15,011,460 | 14,625,923 | ||||||
Total Liabilities | 19,161,456 | 17,195,843 | ||||||
Total Stockholders' Equity | 53,188,731 | 68,710,477 | ||||||
Total Liabilities and Stockholders' Equity | $ | 72,350,187 | $ | 85,906,320 | ||||
Celcuity Inc.
Condensed Statements of Operations
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 8,367,687 | $ | 13,070,108 | $ | 15,064,000 | $ | 15,306,451 | ||||||||
General and administrative | 1,233,040 | 573,360 | 2,044,332 | 1,128,787 | ||||||||||||
Total operating expenses | 9,600,727 | 13,643,468 | 17,108,332 | 16,435,238 | ||||||||||||
Loss from operations | (9,600,727 | ) | (13,643,468 | ) | (17,108,332 | ) | (16,435,238 | ) | ||||||||
Other income (expense) | ||||||||||||||||
Interest expense | (455,445 | ) | (391,187 | ) | (890,446 | ) | (391,210 | ) | ||||||||
Interest income | 95,646 | 1,803 | 103,805 | 2,191 | ||||||||||||
Loss on sale of fixed assets | - | - | - | (263 | ) | |||||||||||
Other income (expense), net | (359,799 | ) | (389,384 | ) | (786,641 | ) | (389,282 | ) | ||||||||
Net loss before income taxes | (9,960,526 | ) | (14,032,852 | ) | (17,894,973 | ) | (16,824,520 | ) | ||||||||
Income tax benefits | - | - | - | - | ||||||||||||
Net loss | $ | (9,960,526 | ) | $ | (14,032,852 | ) | $ | (17,894,973 | ) | $ | (16,824,520 | ) | ||||
Net loss per share, basic and diluted | $ | (0.67 | ) | $ | (1.11 | ) | $ | (1.20 | ) | $ | (1.42 | ) | ||||
Weighted average common shares outstanding, basic and diluted | 14,930,538 | 12,610,917 | 14,923,900 | 11,845,758 | ||||||||||||
Cautionary Statement Regarding Non-GAAP Financial Measures
This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense, issuance of common stock and non-cash interest from net loss and net loss per share. Management excludes these items because they do not impact Celcuity's cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management's method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity's performance or as a measure of liquidity and cash flows.
Celcuity Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and
GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share
(unaudited)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
GAAP net loss | $ | (9,960,526 | ) | $ | (14,032,852 | ) | $ | (17,894,973 | ) | $ | (16,824,520 | ) | ||||
Adjustments: | ||||||||||||||||
Stock-based compensation | ||||||||||||||||
Research and development (1) | 810,664 | 328,077 | 1,261,183 | 583,258 | ||||||||||||
General and administrative (2) | 708,795 | 212,240 | 1,014,547 | 406,157 | ||||||||||||
Issuance of common stock, licensing agreement (3) | - | 5,000,000 | - | 5,000,000 | ||||||||||||
Non-cash interest expense (4) | 188,439 | 174,968 | 385,537 | 174,968 | ||||||||||||
Non-GAAP adjusted net loss | $ | (8,252,627 | ) | $ | (8,317,566 | ) | $ | (15,233,706 | ) | $ | (10,660,137 | ) | ||||
GAAP net loss per share - basic and diluted | $ | (0.67 | ) | $ | (1.11 | ) | $ | (1.20 | ) | $ | (1.42 | ) | ||||
Adjustment to net loss (as detailed above) | 0.12 | 0.45 | 0.18 | 0.52 | ||||||||||||
Non-GAAP adjusted net loss per share | $ | (0.55 | ) | $ | (0.66 | ) | $ | (1.02 | ) | $ | (0.90 | ) | ||||
Weighted average common shares outstanding, basic and diluted | 14,930,538 | 12,610,917 | 14,923,900 | 11,845,758 | ||||||||||||
(1) To reflect a non-cash charge to operating expense for Research and Development stock-based compensation.
(2) To reflect a non-cash charge to operating expense for General and Administrative stock-based compensation.
(3) To reflect a non-cash charge to operating expense for the issuance of common stock related to a licensing agreement.
(4) To reflect a non-cash charge to other expense for amortization of debt issuance and discount costs and PIK interest related to the issuance of a note payable.
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/711772/Celcuity-Inc-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Corporate-Update
FAQ
What recent designation did Celcuity receive for gedatolisib?
How much equity did Celcuity raise in the recent private placement?
What are the key financial results for Celcuity in Q2 2022?
What is the status of the VIKTORIA-1 clinical trial?
